Novel Therapeutic Targets for Antiarrhythmic Drugs by George Edward BillmanNovel Therapeutic Targets for Antiarrhythmic Drugs by George Edward Billman

Novel Therapeutic Targets for Antiarrhythmic Drugs

byGeorge Edward Billman

Hardcover | January 7, 2010

Pricing and Purchase Info


Earn 1145 plum® points

Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores


Profiles potential treatment approaches for cardiac arrhythmias

Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments for cardiac arrhythmias alongside comprehensive presentations of basic cardiac physiology and pharmacology.

Written by leading experts in their research areas, this invaluable resource offers both practitioners and researchers a one-stop guide that brings together previously dispersed information. The text consists of four sections:

  • Section One comprehensively reviews basic cardiac electrophysiology, the mechanisms responsible for arrhythmias in the setting of ischemia, and basic pharmacology of antiarrhythmic drugs.

  • Section Two addresses safety pharmacology, including the concept of "repolarization reserve," safety challenges, and regulatory issues for the development of novel antiarrhythmic drugs.

  • Section Three describes several novel pharmacological targets for antiarrhythmic drugs, including both ion channel and non-ion channel targets.

  • Section Four describes promising non-pharmacological antiarrhythmic interventions including selective cardiac neural disruption or nerve stimulation, aerobic exercise training, and diet (omega-3 fatty acids).

Offering an unparalleled look at the current state and future direction of cardiac arrhythmia treatment, Novel Therapeutic Targets for Antiarrhythmic Drugs provides an important resource to advanced students, working researchers, and busy professionals alike.

George Edward Billman is a professor at The Ohio State University. He is currently an Associate Editor of Pharmacology and Therapeutics, an Editor of Experimental Physiology, and on the editorial boards of Journal of Cardiovascular Pharmacology and Journal of Applied Physiology. Dr. Billman has authored over 125 journal articles and ha...
Title:Novel Therapeutic Targets for Antiarrhythmic DrugsFormat:HardcoverDimensions:586 pages, 9.6 × 6.4 × 1.4 inPublished:January 7, 2010Publisher:WileyLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0470261005

ISBN - 13:9780470261002

Look for similar items by category:

Customer Reviews of Novel Therapeutic Targets for Antiarrhythmic Drugs


Read from the Book

%PDF-1.3 % 1 0 obj > stream hLRmluk{e6?A6-tm6,5Yqlj( !#4[22)uk :aLdA:Y(.am~w 5}a^yeYLFKR?*3xTzu=G rSclc` |? l(''Tq?I?ONTRJYv(CBmx*l?lF:cF?14}k?\r.c(hY&^WaZQrk[?;yGOÏ*!s}TP?HL^VAs)`[pm/$??.?++34 c?0F > endobj 3 0 obj > endobj 4 0 obj > stream hTP=0 + > endobj 6 0 obj > /ProcSet [ /PDF /Text ] /ExtGState > >> endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > /ProcSet [ /PDF /Text ] /ExtGState > >> endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > stream Arbortext Advanced Print Publisher 9.0.114/W Unicode 2009-11-12T09:53:24+05:30 2009-11-12T09:53:24+05:30 application/pdf 9348 209..213 Acrobat Distiller 8.1.0 (Windows) uuid:b76a6738-6215-4efb-8ba3-cdd60c68f366 uuid:0fced4aa-bf28-466b-80bb-1fa45e0b4aae endstream endobj 13 0 obj > /ProcSet [ /PDF /Text ] /ExtGState > >> endobj 14 0 obj > stream hbd`ad`dd pvL) 0q6q5g9@H?I!DW/+.[\b+ f endstream endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > stream h 5rfO6Bu\N3vXtHVxf{|rl?RQ~+!&Hlf#tr"7~|? }WeB7?''[8;b)$^`m.jXi2B X3 X^/ 264,2)dL ;ti&?Q\Ps^9"\\R?mK &rrt%y > endobj 19 0 obj > stream hbd`ad`dd pvL) 0q6q57+i/ vWIp#E LL|?^%}5yWt^} yr^^[]^>{w by3 4] endstream endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > stream hLVipy]bY(nuR;6O?J}H+:Uv$Y((s],X,N AxD[>%?(,3ni?L:g.tO[CC=;v?mCO}t#?z&''V3_okS`sl?~`m?ö??vfomlWjcQ(1;_5 Í8s}y]Vn;&YVp=?9 O\{6w+QLj?-^?ViQ\@Xo=fe>hfCpYs_wVNOus?{}whW;T\m2_27??27[!?s;r 5u??P?0ErY?7 g *\./ORjFgK "l >?4=? !9$By`6p(pO/?Fh''"5~m:eR|$HD *A,? qOm{ ]GWL2Q5].R%rZH3B}'',`>::S[?|Y4u,C}Y\G9?CM&T*lphvx5ul,0BhbT _jsc>ZwAnG"JTp u _\ cCG{@>{ym`??Vg5$;9fslV++] ^?{SuzZPz]?L4V(HM )9@DmT59)gw.bHi) ?"E:3XL?#?y.(&}?p1e5#8-r 6lF` DhJbrhyS3a B8 qFiVR8UEAHV=WI c*CI0D?AztBE!!{LW8DqO?1DA(N`lOc\8)X"IQ?):"DJ8k=??$?`Mii*4F$to?VgrZ 3g *C` Q6e q$N y&0 GI\3L"Ê / > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > stream h?XgtWUO#M)TU$A"(!!DP(ZVZCV(@AdD09x 8w\yVsvOuwWVCmu]ar_Y>d?{_a?}y(6VYj+NVAVVa6VqVV*+-JVC$#Z?al\llm ln!eC. }h?S( uIW?rRE??m{k[o]6m|Xpvxo/{;#>Q9?m{6I#;AGjV7={F xa!r`%xs8l2~0qc [;e *q C_Na$yn?j8)o E 5ydfe>{US}-W9su); =aUmX}x ;]\D''l?t? ^;:}l?8t??T;_x]0W ` p P8:?:Sq?2TS:%03T>A/>0?U_>Yds?YV)_O?%c umj;v4?V7F6nVO;!`WCQMW\?ny?v|z*31zfC{ctmPC?NO, :U8}>+b *V &"?)rJF{ X,c`]@b8eWYqINo O.tX?U00 ,Hs C:C_hVr~pO.LU[23iKI`"v]3p)lir*,t ]T$??8y{GC 8A ~?!`~YU?Y b 5 x?^yL8=gWpF-t1xS5chht[5 x\wG/''97@sP0G ?/?..Oj^L&J??> U?D?TTl?uH EU?|6?,l&u>Z~&wZE% 0ygANb5UsE@OB1Q;Z7sfnC~;iiVv? ^)C7aUE *9{? VdS_01s?9,xjLXB ~NgzpgreL K-bY5 cX& Rb,p~XE ?"*UY;A  6Z?Um$a*?Cp Z?,?.°X:t?6_QjK:zI5A$=:?''5A/}Z "~J !=h}`$L?X`shZÔSh0i)I?Qwqv9 +o3UU m>\DpA?}g?l]rz\iD`1 ???BR&?1E`??KwnUpV ?Gk,W [#?.il?k5j0?+N/IHsUr(1:u,\;boLSyesZAi{WuR?GO:?k^\nX5#{íL"K@n/RH%'' | ?xgLL.W]:>]QK''XJ3V,U#^K qf?]o}"5cGXdxHsINtwsUk$K OH?n3HV.H]!uOp]In?JFjiojl RakR?I%tl7Qe"VYHgIF:NKbYpmC 6)IKpHG| dH T&FzWb2 @g` %0]js??g|%\T_3db2C S5|Ma`Wc0?UZT?+5 Nu?L|@YJEFZBh7y/ C!?I?gy(sH1?6x6 hOWe6Vu|Q''*wc|mccc3YNSg,=;CGj"*)%>6\j}?RU:''lIpFjZ:]/RpB"iRRmf1|0DNj>?zKDifAN?b42?XVkt=B]i kw 5m "F?Kyz|CL)''5h693"%Q !X \%*s G03[ZCT)/($K)2JK6mVL?Q@zb[YrkD7(@%:q Z, C*$?N8*e?48It]#hf&>,u ;bRumHW@adBV,ZedJ] /9 |@Ot:HUM], > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > stream h|Vr6}OT`F;/r}i?IStKYvd X3 fs ? pUe&f nU:X_!&?J+V5,eP''Cu9q?O#MT?ENv,{?wMC5G ,c.6br N (gB] T;\0_W$??!.;Eb2V9?wmsqf .lC7V]|{o0)@c {}UUc1we?]C9sq*6br;F,jW? k4?kvyÔ{MYgB ( c?6l @¯\ /83No?u{?3sYJa(T)2_JjSx3W?''!=8)odW D0\.D||Km-&:?0\xuHx/-|W$k9^G6_59+s?=B?c?T^T?%5O n3z ]wLGt-n~t92 5?/~/*3?/9.91??PB?M@qhx/}P?aN-rk)F>+ATquYfW2M)1 KN6iRA( .:v#B%@Da/"~?Om!P\PC!,'' ?UC/4obNW}.''s(-Qr''\aV=$()-4&G:l q=@?o? j? Z4zL[=-45m`;gu?THvE I"4-S''?EYqlZCI-Z?V 5!(f&?li1_Uu)>"h¥ ,q}X7e?z?eUCU''1P= > êZ|J9~[ }>8Ej5?"qdPo?''@o @"( endstream endobj 34 0 obj > stream hbd`ab`dd pvL) 04wI{X/ ldhW ? @2h?[[l[;}k|p)[|VnXv?KSO''*rTm{ GvE@_%?Gl}K&,Y"Ftf-g}E??}I*`WWnZ2a^?-xR?S\^;!~Ns9~,??)vkM},]]3`? W4?oKk;!?vyd[lblEX4]` EP6}. 6 o q9>j endstream endobj 35 0 obj > endobj 36 0 obj > stream h|Yr#d ZU$ t?g´]*MId($-?/?|{w?{Y g*{Q6 MG{w{{?O,}y(B%?hVxmxC#UY!Lfere;/ bnL0a" i>&hBSa?\IN X?)wo?}9?R?h~8bFZ?>=;0_Oodo?lk6H+cR!2?|[e 1LP_Ez{LMH}*kh2FQS&uT br?]S_e~+kk3''M7g?4yp4PBF ^?&/:p4xci}t8gzZ?X1: ?R\}_x8jI",%W~rAi?}?#"G#HT m; {H_??Jþ2nxZ? 9?$xS??fy.rU.:HbaM IHC J=H&WP.Y/UsO(9pafcD*"aF?8U+l snaGG/0>!?"?hCpA3W| 5!1 O?COeaW^D!F?*#2$X2rf RN%2C^,-%= ''1*hV-I B /(;KBwy[ i W=Z P }]GBmV7?6dmi@YdRtHi $?EelrR6\PD4H 1moy[>??(;"TrV?mK,*w~.W{Lt[v5t`MPIe m?r.qlr?JW* (?8 num??a"wwmu8vD}aw,; ''?%`&4Jlim 0T\=uPVrmWx:N7~u^IC4yD# P{5[?mTE?-RqA?.d5?NM\\`a0r{]?NBnES +weR?R[G83aUqoVzFI? £sSc-9~dZ5 NN VLYbwp (?s( ;o^>+q5Y$HB? +IsBUX| /9e~?Y,?ptlTho!p^ ; 1YVh#Sq?''^@#aA?`Bq4@ )j/j`Hq5 N3q] [P oLT?YqQ~S  ,?XlMUUO mB5QdXU?j?[Sv?2u(C3pORN''A#bX6K~uH,XJbqqz 1 b endstream endobj 37 0 obj > endobj 38 0 obj > stream h?Z?F# Zb2#7 5"MTCMR''&? eHIw5Tg|+tMMm?h"ojn((#C5=Q??B"?[ xR6ei3?#*6d{?f? iD;?:?,4!=2sOJ??oKHEXLGU TG?aNyO"I?}# UNO)"? D'' X@PZs6|- ?}?9/V&?s[ZuL?cH%G~W8?A?Rn2CV(@KO)3N86kkw*WU_A ayd?&* p_BMPqi??^Om\ : -zEb&?Yp(#0L]XK6=6;b`oy-qpmD zeY?1e:]:#>06AIXF}Dc''2Anr5urxJY u=LzIr2en7\aJg@p#/Z]zFPod H)[S?R?{?s2#7,IANm*]"=3s: 2 >eLfqm?i5''7?8s*f%(0*7''!H_Y,:A''en jjy&CfVTt2R$CE0o`g_WapLZ,p+P?!O''KB3+7x(i''+/}?)P^hf; e04 =N*?L?w5A`%Bq G~U#2S?;#@TiwLI7D D>i*xe D>?}d x&MK\fh,?4[?2>mvxdg"JV1N?t=?+X%Q`y$ 1kf"(SAE0 v kO535VS@G"Jwz&.\V0Wy p17?SCQjADN"YR_8N! Nw(8ú/BR&>~3?L.3 `(jnN?$vW?? ?$zfg0:t!faCJ9cx#"1rr~RRNE,?@S,h/?TTiV?x7?H pryoI3aF''"e!V2)?q7oi8 9-Pj~Ks1E*;K$1 *#30jXqEd.}vt:*.vbQ Piu,#`v  ?r?s h+Bq0~`i3`lcM:Bj% tK/.DKnkp&K:5yn>i %wP[aL/?}!O7ni$+ w?r''CK51$S??rH^%\[B]0PiF.6=IUJD9/O+\.qMK > endobj 40 0 obj > endobj 41 0 obj > endobj 42 0 obj > endobj 43 0 obj > endobj 44 0 obj > /ProcSet [ /PDF /Text /ImageB /ImageC /ImageI ] /ExtGState > >> endobj 45 0 obj > endobj 46 0 obj > endobj 47 0 obj > stream xYrF}Wa539q'?H@ R>#) AO_O|{x&YRITN?2KvLuL)qC&D%?3%2/IqJdH?+W?//>,uYFda %YL3- KyMCSw^S>EZZkeI3 z{?? ??d1bs? ?s}{WxBP$cx???jh~#o -?:T~BLM!S(c-7T? al* U8E@X ?_:)SZ;xe/''t+ ?j vGo''BlA%R#y?30]r! hMG¯ AIRx~&Rd G.;53\6@D4h,z!B(B q*L2JGc%ck BXuLFb/!aIXDB p IS*G|\z*?oE V2Z )* $0A\jOnD[l@M\Q*+W/f::}LF]h?*TeHME3c9 WFw l(}]v*y8 k GA =W F]X#Qv5-1H*Y!l`J}qw?4x2T|c?)}clC>v0P%?`LB(5JI V ?=?=(Wi4|UZ&8K/5?ydc?Ea? 4e|m&: ?W/VwWZ|Kdc?="0AYo?>gu(a}+T=@i$X+7VTZhKzDxp N+t_(Y&YQk3.9Ggj`?z{_~uC9#Q(! "=nHIÏ~wo[^I~x^ endstream endobj xref 0 48 0000000000 65535 f 0000000044 00000 n 0000001027 00000 n 0000001198 00000 n 0000001406 00000 n 0000001691 00000 n 0000002041 00000 n 0000002180 00000 n 0000002551 00000 n 0000002637 00000 n 0000002755 00000 n 0000003017 00000 n 0000003106 00000 n 0000006663 00000 n 0000006792 00000 n 0000006982 00000 n 0000007227 00000 n 0000007268 00000 n 0000008798 00000 n 0000009362 00000 n 0000009592 00000 n 0000009801 00000 n 0000009973 00000 n 0000010344 00000 n 0000010516 00000 n 0000013983 00000 n 0000014176 00000 n 0000014258 00000 n 0000014431 00000 n 0000020410 00000 n 0000020673 00000 n 0000020846 00000 n 0000020915 00000 n 0000021198 00000 n 0000022903 00000 n 0000023381 00000 n 0000023554 00000 n 0000026897 00000 n 0000027126 00000 n 0000031221 00000 n 0000031431 00000 n 0000031971 00000 n 0000031999 00000 n 0000033167 00000 n 0000033364 00000 n 0000033561 00000 n 0000033630 00000 n 0000033710 00000 n trailer ] /Info 37 0 R >> startxref 36897 %%EOF

Table of Contents



1. Introduction (George E. Billman).

2. Myocardial K+ Channels: Primary Determinants of Action Potential Repolarization (Noriko Niwa and Jeanne Nerbonne).

2.1 Introduction.

2.2 Action Potential Waveforms and Repolarizing K+ Currents.

2.3 Functional Diversity of Repolarizing Myocardial K+ Channels.

2.4 Molecular Diversity of K+ Channel Subunits.

2.5 Molecular Determinants of Functional Cardiac Ito Channels.

2.6 Molecular Determinants of Functional Cardiac IK Channels.

2.7 Molecular Determinants of Functional Cardiac Kir Channels.

2.8 Other Potassium Currents Contributing to Action Potential Repolarization.

3. The "Funny" Pacemaker Current (Andrea Barbuti, Annalisa Bucchi, Mirko Baruscotti, and Dario DiFrancesco).

3.1 Introduction: The Mechanism of Cardiac Pacemaking.

3.2 The "Funny" Current.

3.3 Molecular Determinants of the If Current.

3.4 Blockers of Funny Channels.

3.5 Genetics of HCN Channels.

3.6 HCN-Based Biological Pacemakers.

4. Arrhythmia Mechanisms in Ischemia and Infarction (Ruben Coronel, Wen Dun, Penelope A. Boyden, and Jacques M.T. de Bakker).

4.1 Introduction.

4.2 Arrhythmogenesis in Acute Myocardial Ischemia.

4.3 Arrhythmogenesis During the First Week Post MI.

4.4 Arrhythmia Mechanisms in Chronic Infarction.

5. Antiarrhythmic Drug Classification (Cynthia A. Carnes).

5.1 Introduction.

5.2 Sodium Channel Blockers.

5.3 Inhibitors of the Fast Sodium Current with Rapid Kinetics (Vaughan Williams Class Ib).

5.4 Inhibitors of the Fast Sodium Current with Slow Kinetics (Vaughan Williams Class Ic).

5.5 Inhibitors of Repolarizing K+ Currents (Vaughan Williams Class III).

5.6 IKur Blockers.

5.7 Inhibitors of Calcium Channels.

5.8 Inhibitors of Adrenergically-Modulated Electrophysiology.

5.9 Adenosine.

5.10 Digoxin.

5.11 Conclusions.

6. Repolarization Reserve and Proarrhythmic Risk (András Varró).

6.1 Definitions and Background.

6.2 The Major Players Contributing to Repolarization Reserve.

6.3 Mechanism of Arrhythmia Caused By Decreased Repolarization Reserve.

6.4 Clinical Significance of the Reduced Repolarization Reserve.

6.5 Repolarization Reserve as a Dynamically Changing Factor.

6.6 How to Measure the Repolarization Reserve.

6.7 Pharmacological Modulation of the Repolarization Reserve.

6.8 Conclusion.

7. Safety Challenges in the Development of Novel Antiarrhythmic Drugs (Gary Gintant and Zhi Su).

7.1 Introduction.

7.2 Review of Basic Functional Cardiac Electrophysiology.

7.3 Safety Pharmacology Perspectives on Developing Antiarrhythmic Drugs.

7.4 Proarrhythmic Effects of Ventricular Antiarrhythmic Drugs.

7.5 Avoiding Proarrhythmia with Atrial Antiarrhythmic Drugs.

8. Safety Pharmacology and Regulatory Issues in the Development of Antiarrhythmic Medications (Armando Lagrutta and Joseph J. Salata).

8.1 Introduction.

8.2 Basic Physiological Considerations.

8.3 Historical Considerations.

8.4 Opportunities for Antiarrhythmic Drug Development in the Present Regulatory Environment.

9. Ion Channel Remodeling and Arrhythmias (Takeshi Aiba and Gordon F. Tomaselli).

9.1 Introduction.

9.2 Molecular and Cellular Basis for Cardiac Excitability.

9.3 Heart Failure—Epidemiology and the Arrhythmia Connection.

9.4 K+ Channel Remodeling in Heart Failure.

9.5 Ca2+ Handling and Arrhythmia Risk.

9.6 Intracellular [Na+] in HF.

9.7 Gap Junctions and Connexins.

9.8 Autonomic Signaling.

9.9 Calmodulin Kinase.

9.10 Conclusions.

10. Redox Modification of Ryanodine Receptors in Cardiac Arrhythmia and Failure: A Potential Therapeutic Target (Andriy E. Belevych, Dmitry Terentyev, and Sandor Györke).

10.1 Introduction.

10.2 Activation and Deactivation of Ryanodine Receptors During Normal Excitation-Contraction Coupling.

10.3 Defective Ryanodine Receptor Function is Linked to Proarrhythmic Delayed Afterdepolarizations and Calcium Alternans.

10.4 Genetic and Acquired Defects in Ryanodine Receptors.

10.5 Effects of Thiol-Modifying Agents on Ryanodine Receptors.

10.6 Reactive Oxygen Species Production and Oxidative Stress in Cardiac Disease.

10.7 Redox Modification of Ryanodine Receptors in Cardiac Arrhythmia and Heart Failure.

10.8 Therapeutic Potential of Normalizing Ryanodine Receptor Function.

11. Targeting Na+/Ca2+ Exchange as an Antiarrhythmic Strategy (Gudrun Antoons, Rik Willems, and Karin R. Sipido).

11.1 Introduction.

11.2 Why Target NCX in Arrhythmias?

11.3 When Do We See Triggered Arrhythmias?

11.4 What Drugs are Available?

11.5 Experience with NCX Inhibitors.

11.6 Caveat—the Consequences on Ca2+ Handling.

11.7 Need for More Development.

12. Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII)—Modulation of Ion Currents and Potential Role for Arrhythmias (Dr. Lars S. Maier).

12.1 Introduction.

12.2 Evolving Role of Ca2+/CaMKII in the Heart.

12.3 Activation of CaMKII.

12.4 Role of CaMKII in ECC.

12.5 Role of CaMKII for Arrhythmias.

12.6 Summary.

13. Selective Targeting of Ventricular Potassium Channels for Arrhythmia Suppression: Feasible or Risible? (Hugh Clements-Jewery and Michael Curtis).

13.1 Introduction.

13.2 Effects of K+ Channel Blockade on APD and Arrhythmogenesis.

13.3 Conclusions/Future Directions.

14. Cardiac Sarcolemmal ATP-sensitive Potassium Channel Antagonists: A Class of Drugs that May Selectively Target the Ischemic Myocardium (George E. Billman).

14.1 Introduction.

14.2 Effects of Myocardial Ischemia on Extracellular Potassium.

14.3 Effect of Extracellular Potassium on Ventricular Rhythm.

14.4 Effect of ATP-sensitive Potassium Channel Antagonists on Ventricular Arrhythmias.

14.5 Summary.

15. Mitochondrial Origin of Ischemia-Reperfusion Arrhythmias (Brian O'Rourke, PHD).

15.1 Introduction.

15.2 Mechanisms of Arrhythmias.

15.3 Ischemia-Reperfusion Arrhythmias.

15.4 Mitochondrial Criticality: The Root of Ischemia-Reperfusion Arrhythmias.

15.5 KATP Activation and Arrhythmias.

15.6 Metabolic Sinks and Reperfusion Arrhythmias.

15.7 Antioxidant Depletion.

15.8 Mitochondria as Therapeutic Targets.

16. Cardiac Gap Junctions: A New Target for New Antiarrhythmic Drugs: Gap Junction Modulators (Anja Hagen and Stefan Dhein).

16.1 Introduction.

16.2 The Development of Gap Junction Modulators and AAPs.

16.3 Molecular Mechanisms of Action of AAPs.

16.4 Antiarrhythmic Effects of AAPs.

16.5 Site- and Condition-Specific Effects of AAPs; Effects in Ischemia or Simulated Ischemia.

16.6 Chemistry of AAPs.

16.7 Short Overview About Cardiac Gap Junctions.

16.8 Gap Junction Modulation as a New Antiarrhythmic Principle.

17. Novel Pharmacological Targets for the Management of Atrial Fibrillation (Alexander Burashnikov and Charles Antzelevitch).

17.1 Introduction.

17.2 Novel Ion Channel Targets for Atrial Fibrillation Treatment.

17.3 Upstream Therapy Targets for Atrial Fibrillation.

17.4 Gap Junction as Targets for AF Therapy.

17.5 Intracellular Calcium Handling and AF.

18. IKur, Ultra-rapid Delayed Rectifier Potassium Current: A Therapeutic Target for Atrial Arrhythmias (Arun Sridhar and Cynthia A. Carnes).

18.1 Introduction.

18.2 Molecular Biology of the Kv1.5 Channels.

18.3 IKur as a Therapeutic Target.

18.4 Organic Blockers of IKur.

18.5 Conclusions.

19. Non-Pharmacologic Manipulation of the Autonomic Nervous System in Human for the Prevention of Life-Threatening Arrhythmias (Peter J. Schwartz).

19.1 Introduction.

19.2 Sympathetic Nervous System.

19.3 Parasympathetic Nervous System.

19.4 Conclusion.

20. Effects of Endurance Exercise Training on Cardiac Autonomic Regulation and Susceptibility to Sudden Cardiac Death: A Nonpharmacological Approach for the Prevention of Ventricular Fibrillation (George E. Billman).

20.1 Introduction.

20.2 Exercise and Susceptibility to Sudden Death.

20.3 Cardiac Autonomic Neural Activity and Sudden Cardiac Death.

20.4 b2-Adrenergic Receptor Activation and Susceptibility to VF.

20.5 Effect of Exercise Conditioning on Cardiac Autonomic Regulation.

20.6 Effect of Exercise Training on Myocyte Calcium Regulation.

20.7 Summary and Conclusions.

21. Dietary Omega-3 Fatty Acids as a Nonpharmacological Antiarrhythmic Intervention (Barry London and J. Michael Frangiskakis).

21.1 Introduction.

21.2 Fatty Acid Metabolism.

21.3 Cellular Mechanisms.

21.4 Animal Studies.

21.5 Clinical Studies.

21.6 Future Directions.


General Index.

Index of Drug and Chemical Names.

Editorial Reviews

"George Billman has assembled a terrific book that will serve the needs of students, clinical and research faculty with interests in cardiac arrhythmias, antiarrhythmic drugs and ion channel biology." —Mark E. Anderson, M.D., Ph.D. Professor, Departments of Internal Medicine and Molecular Physiology & Biophysics Head, Department of Internal Medicine François M. Abboud Chair in Internal Medicine "The information presented in each individual chapter is of superb quality, still providing the information in such a detailed way that even the knowledge of the specialists in the field will be challenged. The topics covered, however, are so broad that the mentioned specialist will also find chapters of great interest to his common knowledge in other fields. In this era of PubMed, the younger scientists will be pleased to find detailed referencing, including papers going back many decades, revealing information well in the last century. Therefore, I recommend this book to individuals still interested in the mechanism behind arrhythmias and the way that this knowledge can be applied to new therapeutic strategies." —Marc Vos, PhD, University Medical Center Utrecht